南予医学雑誌　第18巻

83/91

南予医誌　Vol.18　No. １　2017－82－10）　 Sasaki K， Jabbour EJ， Ravandi F， et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as front-line therapy for patients with Phila-delphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis．Cancer 2016; 122: 3650-3656．11）　 Weinberg OK， Arber DA. Mixed-phenotype acute leukemia: historical overview and a new denition. Leuke-mia 2010; 24: 1844-1851．12）　 Ottmann OG， Pfeifer H. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia（Ph＋ALL）. Hematology Am Soc Hematol Educ Program 2009: 371-381．13）　 Quintas-Cardama A， Kantarjian H， Ravandi F， et al．Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy．Cancer 2009; 115: 2482-2490．14）　 Nazha A， Romo CG， Kantarjian H， et al. The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia, Haemato-logica 2013; 98: e131．15）　 Moslehi JJ， Deininger M. Tyrosine Kinase Inhibitor-Associated Cardio-vascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol 2015; 33: 4210-4218．16）　 Munker R， Brazauskas R， Wang HL， et al．Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia．Biol Blood Marrow Transplant 2016; 22: 1024-1029．17）　 Shimizu H， Saitoh T， Machida S， et al. Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: re-sults of a matched-pair analysis. Eur J Haematol 2015; 95: 455-460．